Experimental Medicine Training Initiative
  log in
  log in
Cambridge University
Cambridge University



Who's who on the EMI Training Committee

Dr Joseph CheriyanDr Joseph Cheriyan – EMI Training Lead 

Consultant Physician & Clinical Pharmacologist at Addenbrooke’s Hospital, Associate Lecturer, University of Cambridge, Director of the Cardiovascular Trials Office, Vice Chair of the Cambridge Research Ethics Committee.

Dr Cheriyan has been a Consultant Physician and Clinical Pharmacologist at Addenbrooke’s Hospital, Cambridge, UK since 2006, and an Associate Lecturer in the Department of Medicine, University of Cambridge. He trained initially in Sheffield, and subsequently in Nottingham and London before completing his specialist training Cambridge.

He is an active clinical researcher with interests in cardiovascular medicine particularly vascular function and inflammation. He is one of a few clinical triallists working on early phase experimental medicine studies of novel therapeutics, and has a unique post which combines close collaboration with industrial partners on the Addenbrooke’s Biomedical Campus. His clinical service commitments are to the Department of Acute Medicine at Addenbrooke’s Hospital. He is the Vice Chair of the local Research Ethics Committee, a member of the Management Board of the Cambridge Clinical Trials Unit and a Senior Physician and Clinical Pharmacologist to the GSK CUC in Cambridge. He has co-authored the Oxford Specialist Handbook on Hypertension and is also co-founder of the Cambridge Medical Seminars. Apart from work, he is a keen traveller and connoisseur of fine dining!

Dr Paolo ViciniDr Paolo Vicini

Senior Director of Clinical Pharmacology and DMPK (Drug Metabolism and Pharmacokinetics), MedImmune.

Dr Paolo Vicini is Senior Director of Clinical Pharmacology and DMPK (Drug Metabolism and Pharmacokinetics) at MedImmune. Previously, Paolo was a Research Fellow with Pfizer in San Diego. His research was on quantitative pharmacology approaches, with emphasis on translational PK-PD (oncology molecularly targeted agents). Before Pfizer, Paolo was a Bioengineering faculty member at the University of Washington, Seattle, where he remains an Affiliate Faculty in Bioengineering and Pharmaceutics.

Paolo served on the NIH Biomedical Computing and Health Informatics Study Section (2005-2009). He is a Fellow of the American Association of Pharmaceutical Scientists (2011). He has published, to date, 120 peer reviewed articles., is an Associate Editor of Pharmacometrics and Systems Pharmacology and is on the Advisory Editorial Board of the Journal of Pharmacokinetics and Pharmacodynamics and of Clinical Pharmacology and Therapeutics. He is a member of the American Society of Clinical Pharmacology and Therapeutics, the American Association of Pharmaceutical Scientists, the Biomedical Engineering Society, the IEEE Engineering in Medicine and Biology Society, the International Society of Pharmacometrics, the International Society for the Study of Xenobiotics, the American Diabetes Association and of Beta Gamma Sigma.

Dr Phil AmberyDr Phil Ambery

Senior Director, Clinical Biologics, Medimmune

Dr Ambery has considerable experience across all phases of clinical development in cardiovascular and metabolic diseases (CVMD) in the pharmaceutical industry.

Having worked in medical affairs, early and latedevelopment for GSK from 2001-2014, he joined Medimmune where he is the lead member for the CVMD clinical group in Cambridge.

He has a particular interest in incretins for the treatment of Type 2 diabetes and in Type 1 diabetes immune modulation.

He is a specialist partner for the General Medical Council in academic or research certification, taking a particular interest in the licensing of doctors via the academic route, and still practises as an Acute Medicine Physician in Addenbrookes.

Dr Kevin O’ShaughnessyDr Kevin O’Shaughnessy

Reader in Clinical Pharmacology and Investigator in the division of Experimental Medicine and Immunotherspeutics (EMIT), University of Cambridge. Honorary Consultant Physician, Cambridge University Hospitals NHS Foundation Trust. Fellow of Gonville and Caius College, University of Cambridge. Training Programme Director, Clinical Pharmacology & Therapeutics (Eastern Deanery)

Dr O’Shaughnessy is interested in the molecular genetics of essential hypertension and pre-eclampsia, and the role of salt in hypertension. He is currently the Training Programme Director for Clinical Pharmacology for the Eastern Region.

Prof Ian WilkinsonProf Ian Wilkinson

Professor of Therapeutics and Head, Division of Experimental Medicine and Immunotherapeutics (EMIT), University of Cambridge. Director of the Cambridge Clinical Trials Unit, Director of the Office of Translational Research, University of Cambridge. Fellow of Trinity Hall, University of Cambridge

Focuses on understanding the biological pathways underlying systemic hypertension and arteriosclerosis, with a strong emphasis on basic physiology, experimental/translational medicine and early phase interventional clinical trials. My group has expertise in vascular physiology/pharmacology, hypertension, endothelial biology and trial design.

Mrs Elizabeth McIntyre – EMI Training Coordinator

Graduate Programme Manager in the Graduate and Clinical Academic Training Office, School of Clinical Medicine.

ejm45@medschl.cam.ac.uk  Tel: 01223 761495


Copyright ©2018 Experimental Medicine Training Initiative - Cambridge University Hospitals. All rights reserved.